Drugs / CD5-targeted CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06874946 | Feb 2025 → Dec 2026 expected | T lymphoblastic leukemia/lymphoma, T-cell non-Hodgkin lymphoma | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD5-targeted CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06874946 ↗ |
| Modality | Cell therapy | “Nanobody-Based CD5 Chimeric Antigen Receptor (CAR) T-cell therapy” NCT06874946 ↗ |
| Target | CD5 | “CD5-targeted CAR-T cells” NCT06874946 ↗ |